II. Epidemiology
- Endemic Regions (tropical Americas)
- Mexico
- Central America
- South America
- Southern Texas
-
Prevalence (estimated)
- Endemic regions: 8-11 Million infected
- United States: 300,000 infected
- Most cases are via immigration and travel
- However vector-borne transmission has occurred in Southern U.S.
- Bern (2011) Clin Microbiol Rev 24(4): 655-81 [PubMed]
III. Pathophysiology
- Organism
- Protozoa: Trypanosoma cruzi
- African Trypanosomiasis (African Sleeping Sickness) is also caused by a Trypanosome
- However, African Trypanosomiasis differs greatly in its manifestations from American Trypanosomiasis
- Wild animal reservoirs (in addition to humans)
- Rodents
- Opossums
- Armadillos
- Transmission: Vector borne (primary source)
- Triatomine bug (reduviid bug, assassin bug or kissing bug) is an Insect that feeds on blood
- Triatomine bugs nest in the crevices of mud and clay houses
- Triatomine bugs are nocturnal and feed on humans as they sleep
- Acquires T. cruzi via ingested blood containing the Parasite as trypomastigote
- Trypomastigotes differentiate inside the Insect midgut into epimastigotes which further multiply
- Epimastigotes differentiate into the infective form, metacyclic trypomastigotes
- Insect carrying the Parasite defecates into a human wound site or mucous membranes (e.g. Conjunctiva)
- Parasite is initially transmitted from Insect to human via Insect feces as metacyclic trypomastigote
- Metacyclic trypomastigotes differentiate into amastigotes on human cell penetration
- Metacyclic trypomastigotes are motile with a flagellum and undulating membrane
- Amastigotes are rounded forms, without flagella
- Amastigotes multiply via binary fission
- Releases trypomastigotes to infect other human cells (Macrophages, Lymph Nodes)
- Spreads via blood to distant organs
- Triatomine bug (reduviid bug, assassin bug or kissing bug) is an Insect that feeds on blood
- Transmission: Other mechanisms
- Congenital (vertical transmission)
- U.S. congenital infections per year: 300
- Blood Transfusion
- U.S. Blood supply is screened for Trypanosoma cruzi since 2007
- Organ transplant
- Contaminated food
- Lab exposure
- Congenital (vertical transmission)
IV. Findings: Acute Phase
- Often asymptomatic
- Duration: 4-8 weeks after infection
- Chagoma
- Forms at skin Parasite entry site
- Hard, red, firm skin with Localized Edema
- Rowana's Sign (20-50% of acute cases)
- Painless unilateral eye swelling
- Non-specific febrile illness (variably present)
- Fever
- Malaise
- Headache
- Anorexia
- Lymphadenopathy
- Non-pruritic rash
- Severe manifestations
- Persistent Sinus Tachycardia or other Arrhythmia
- Severe meningoencephalitis (esp. young patients)
V. Findings: Chronic Phase
VI. Complications
- Cardiac
- Conduction abnormalities
- Heart Block risks
- Ventricular Tachycardia risk
- Apical aneurysm
- Dilated Cardiomyopathy or Congestive Heart Failure (late finding)
- Thromboembolism
- Pericardial Effusion
- Conduction abnormalities
- Gastrointestinal
- Megaesophagus
- Toxic Megacolon
- Neurologic
- Infants with congenital infection (vertical transmission from mother)
- Often asymptomatic
- IUGR with low birth weight in some cases
- Low APGAR Scores at birth
- Anemia
- Thrombocytopenia
- Hepatomegaly
- Splenomegaly
- Myocarditis (rare)
- Meningoencephalitis (rare)
VII. Labs
- Acute infection
- Peripheral Smear (Light Microscopy)
- Peripheral blood (or anticoagulated cord blood) for trypomastigotes
- Polymerase chain reaction (PCR)
- Highly specific and may be positive before Peripheral Smear demonstrates organisms
- Peripheral Smear (Light Microscopy)
- Chronic infection
- Organism counts too low in chronic disease to be detectable by Peripheral Smear or PCR
- Serology tests for T. cruzi
- Positive on at least two different Serologic Tests (insufficient efficacy of any individual test)
- Enzyme-linked immunosorbent assay (ELISA)
- Immunofluorescent Antibody assay
- Adjunctive diagnostic modalities
- Echocardiogram (for Heart Failure)
- Electrocardiogram (for Arrhythmia)
- Upper endoscopy (for megaesophagus)
VIII. Diagnostics
-
Electrocardiogram
- Obtain at time of diagnosis and as needed
IX. Management: Antiparasitic
- Protocol
- Treat immediately if not contraindicated
- Course of Antiparasitic Agent treatment is 60-90 days
- Perform physical exam to evaluate for end-organ involvement
- Electrocardiogram
- Contraindications to Antiparasitic therapy
- Pregnancy
- Severe hepatic insufficiency
- Severe Renal Insufficiency
- Indications: Acute Chagas Disease
- Treat all acute Chagas Disease cases (if not contraindicated)
- Treat congenitally acquired Chagas Disease
- Treat Immunocompromised patients with reactivated Chagas Disease
- Indications: Chronic Chagas Disease
- Chronic Chagas Disease is far less responsive to treatment than acute Chagas Disease
- All patients under age 18 years old with chronic Chagas Disease
- Patients under age 50 years old with chronic Chagas Disease and no advanced Cardiomyopathy
- Patients over age 50 years have had longterm infection that is unlikely to be cured with medication
- Consult CDC or infectious disease for management recommendations regarding specific case management
- Medications (available in U.S. through CDC)
- Contraindications (see above)
- Pregnancy and Lactation
- Severe renal dysfunction
- Severe liver dysfunction
- Only two agents have proven efficacy
- Benznidazole
- FDA approved for ages 2-12 years old
- Nifurtimox (Lampit)
- FDA approved from birth to 18 years (weight >5 lb 8 oz or 2.5 kg)
- Benznidazole
- Contraindications (see above)
- Adverse effects from treatment agents
- Weight loss
- Anorexia
- Polyneuropathy or Peripheral Neuropathy
- Rash
- Nausea
X. Management: Complications
-
Congestive Heart Failure
- See Congestive Heart Failure Exacerbation Management
- Exercise caution with Beta Blockers (higher risk of Bradycardia)
- Atrial Arrythmias
- Cardiac Pacemaker (Heart Block, Sick Sinus Syndrome)
- Ventricular Arrhythmias (e.g. Ventricular Tachycardia)
- Amiodarone
- Catheter ablation and placement of IACD
-
Thromboembolism risk
- Consider antithrombotic therapy
XI. Screening
- U.S. Immigrants from Mexico, Central America or South America
- Children of mothers with Chagas Disease
- Blood donors in U.S.
XII. Prevention
- Blood donors in the United States are screened for T cruzi (since 2007)
- Not allowed to donate blood if positive
- Endemic area strategies
- Clean rooms
- Mosquito nets
- Insecticides
XIII. Resources
- CDC Trypanosomiasis
XIV. References
- Gladwin, Trattler and Mahan (2014) Clinical Microbiology, Medmaster, Fl, p. 349-51
- Wang and Nguyen (2017) Crit Dec Emerg Med 31(9):13-8
- Bern (2007) JAMA 298(18): 2171-81 [PubMed]
- Cantey (2021) Am Fam Physician 104(3): 277-87 [PubMed]
- Rassi (2010) Lancet 375(9723): 1388-1402 [PubMed]
- Woodhall (2014) Am Fam Physician 89(10): 803-11 [PubMed]